is the worldwide lifetime prevalence of ocd roughly 1% to just over 2%?
“Its worldwide lifetime prevalence is roughly 1 to just over 2%.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-10-14, at 01:11. hear it in context →
the episode: Glutamatergic Augmentation in OCD (at 01:11). we link the show's own page; we do not re-host audio.
first, the part that holds
the range the host gave matches the main record. a meta-analysis of 34 community studies from around the world puts lifetime OCD prevalence at 1.3%, and the large US national surveys put it at 2.3%. "roughly 1 to just over 2%" covers both.
what we found when we went and looked
we read the 2020 worldwide meta-analysis in the Journal of Clinical Psychiatry (34 community-based studies, searched through January 2017). it gives a pooled lifetime prevalence of 1.3%, with 1.5% in women and 1.0% in men. the US National Comorbidity Survey Replication found 2.3% lifetime for DSM-IV OCD, and NIMH reports the same figure. an earlier seven-country study found most countries between 1.9% and 2.5%. one result sits above the range: a 2025 World Mental Health survey across 10 countries reported a pooled lifetime prevalence of 4.1%, though most of those cases were mild or very mild.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the lower end of worldwide lifetime OCD prevalence is roughly 1% | confirmed | the 2020 meta-analysis of 34 community-based epidemiological studies worldwide gives a pooled lifetime prevalence of 1.3% (women 1.5%, men 1.0%), current prevalence of 1.1% and period prevalence of 0.8%. its search ended in January 2017, so it does not include the 2025 World Mental Health data. [1] |
| the upper end of worldwide lifetime OCD prevalence is just over 2% | confirmed | the US National Comorbidity Survey Replication found 2.3% lifetime and 1.2% past-year for DSM-IV OCD. NIMH reports these figures, from 9,282 respondents interviewed in 2001-2003. the 1980s US survey also found 2.3%, and the seven-country study found most countries between 1.9% (Korea) and 2.5% (Puerto Rico), as cited in the 2025 World Mental Health paper. these are a handful of mostly high-income countries using older criteria, not a census of the world. [2][3][4] |
| the 1-2% range is the ceiling of current estimates | undersold | the 2025 World Mental Health surveys (26,136 adults, 10 countries, DSM-IV, CIDI 3.0) report a weighted pooled lifetime prevalence of 4.1% and a 12-month prevalence of 3.0%. country figures range from 0.4% (Murcia, Spain) to 5.5% (Shenzhen, China). most 12-month cases rated mild (47.0%) or very mild (27.5%). the authors note concerns that lay-administered interviews can overestimate OCD, while reporting good agreement with clinician diagnoses. the host did not say the range was a ceiling, so this row is context, not a clause of the claim. [4] |
both directions
for the speaker: the most comprehensive pooled estimate we could read, a worldwide meta-analysis of 34 community studies, gives 1.3% lifetime. the best-known national survey, the US National Comorbidity Survey Replication, gives 2.3% lifetime, a figure NIMH also publishes. the older seven-country study found most countries between 1.9% and 2.5%. together these sit within "roughly 1 to just over 2%".
against: the newest large cross-national survey points higher. the 2025 World Mental Health analysis of 10 countries reports a pooled lifetime prevalence of 4.1%, nearly double the top of the host's range, and up to 5.5% in one Chinese city. single countries can also fall below 1%: 0.4% in Murcia, Spain in the 2025 surveys, and 0.7% in Taiwan in the older seven-country study. "worldwide" hides wide spread between countries, and a range of 1-2% can make the estimate look more settled than it is.
what this cannot say
every figure here comes from structured interviews in community samples, mostly given by lay interviewers. whether those interviews over- or under-count OCD is still argued over. the studies used different criteria (DSM-III, DSM-IV) and cover a minority of the world's countries, few of them low-income. the meta-analysis search stopped in January 2017. we read the meta-analysis and the seven-country figures through abstracts and a secondary citation, not the full text, and we did not check DSM-5-era surveys beyond these. lifetime prevalence also depends on people remembering past symptoms, which tends to undercount.
sources, each one fetched and read
- Fawcett EJ, Power H, Fawcett JM. Women are at greater risk of OCD than men: a meta-analytic review of OCD prevalence worldwide. Journal of Clinical Psychiatry, 2020;81(4):19r13085. doi:10.4088/JCP.19r13085. PMID 32603559 What we read there: 34 community-based studies (search through January 2017); pooled lifetime OCD prevalence 1.3%, current 1.1%, period 0.8%; women 1.5% vs men 1.0% lifetime, women 1.6 times more likely to experience OCD. Fetched 2026-10-16 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/32603559/
- Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry, 2008. PMC2797569 What we read there: lifetime prevalence of DSM-IV OCD 2.3% (SE 0.3); 12-month prevalence 1.2% (SE 0.3); 28.2% of respondents reported obsessions or compulsions at some point in their lives. Fetched 2026-10-16 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC2797569/
- National Institute of Mental Health. Obsessive-compulsive disorder (OCD) statistics. NIMH, based on the National Comorbidity Survey Replication 2001-2003 What we read there: an estimated 1.2% of U.S. adults had OCD in the past year; lifetime prevalence of OCD among U.S. adults was 2.3%; 9,282 respondents, WMH-CIDI, DSM-IV. Fetched 2026-10-16 (HTTP 200). https://www.nimh.nih.gov/health/statistics/obsessive-compulsive-disorder-ocd
- Stein DJ et al. Obsessive-compulsive disorder in the World Mental Health surveys. BMC Medicine, 2025. doi:10.1186/s12916-025-04209-5. PMC12239380 What we read there: across the 10 countries surveyed (26,136 adults), OCD has a combined lifetime prevalence of 4.1% and 12-month prevalence of 3.0%; range 0.4% (Murcia, Spain) to 5.5% (Shenzhen, China); most 12-month cases mild (47.0%) or very mild (27.5%); cites earlier cross-national lifetime rates of 1.9% (Korea) to 2.5% (Puerto Rico) and NCS-R 2.3%. Fetched 2026-10-16 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC12239380/
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam